CHF24.95
20.16% yesterday
SIX Swiss Exchange, Nov 15, 05:31 pm CET
ISIN
CH0325814116
Symbol
KURN
Sector
Industry

Kuros Biosciences Target price 2024 - Analyst rating & recommendation

Kuros Biosciences Classifications & Recommendation:

Buy
100%

Kuros Biosciences Price Target

Target Price CHF19.00
Price CHF24.95
Deviation
Number of Estimates 1
1 Analyst has issued a Kuros Biosciences price target 2025. The average Kuros Biosciences target price is CHF19.00. This is lower than the current stock price.
A rating was issued by 1 analysts: 1 Analysts recommend Kuros Biosciences to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kuros Biosciences stock has an average upside potential 2025 of . Most analysts recommend the Kuros Biosciences stock at Purchase.

Sales and Margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million CHF 33.56 77.20
86.55% 130.04%
EBITDA Margin -18.33% 11.92%
55.27% 165.05%

1 Analyst has issued a sales forecast Kuros Biosciences 2024 . The average Kuros Biosciences sales estimate is

CHF77.2m
Unlock
. This is
46.94% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF77.2m 46.94%
Unlock
, the lowest is
CHF77.2m 46.94%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 CHF33.6m 86.55%
2024
CHF77.2m 130.04%
Unlock
2025
CHF123m 58.81%
Unlock
2026
CHF160m 30.10%
Unlock

1 Analyst has issued an EBITDA forecast Kuros Biosciences 2024 . The average Kuros Biosciences EBITDA estimate is

CHF9.2m
Unlock
. This is
500.00% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF9.2m 500.00%
Unlock
, the lowest is
CHF9.2m 500.00%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 CHF-6.2m 16.55%
2024
CHF9.2m 249.59%
Unlock
2025
CHF16.3m 77.17%
Unlock
2026
CHF25.9m 58.90%
Unlock

EBITDA Margin

2023 -18.33% 55.27%
2024
11.92% 165.05%
Unlock
2025
13.30% 11.58%
Unlock
2026
16.24% 22.11%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
EV/Sales 12.03

Based on analysts' sales estimates for 2024, the Kuros Biosciences stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

12.03
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
12.14
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.68 218.56%
2024
12.03 31.96%
Unlock
2025
7.58 37.03%
Unlock
2026
5.82 23.14%
Unlock

P/S ratio

Current 17.84 199.62%
2024
12.14 31.94%
Unlock
2025
7.65 37.03%
Unlock
2026
5.88 23.14%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today